Ticker Symbol: VTYX
Ventyx Biosciences Inc
$21.75 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001851194
Company Profile
Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
Sector: Manufacturing
Industry: Medicinal and Botanical Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 662 Encinitas Boulevard
Website: ventyxbio.com
CEO: Raju S. Mohan
Tags:
N/A
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $30.20
Change:
-$0.97
(
-3.13%)
Days Range: $29.17 - $31.01
Beta: 1.17
52wk. High: $47.25
52wk. Low: $16.54
Ytd. Change -8.04%
50 Day Moving Average: $29.66
200 Day Moving Average: $33.33
Shares Outstanding: 58710000
Valuation
Market Cap: 177.3B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A